783 results on '"Punt, C."'
Search Results
302. 04 Immunization of melanoma patients with peptide-pulsed dendritic cells (DC)
- Author
-
Punt, C. J. A., primary, de Vries, I. J. M., additional, Eggert, A. A. O., additional, Scharenborg, N. H., additional, Verstraten, H. G. G., additional, Ruiter, D. J., additional, Adema, G. J., additional, and Figdor, C. G., additional
- Published
- 1999
- Full Text
- View/download PDF
303. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR
- Author
-
de Vries, T J, primary, Fourkour, A, additional, Punt, C J A, additional, Locht, L T F van de, additional, Wobbes, T, additional, Bosch, S van den, additional, Rooij, M J M de, additional, Mensink, E J B M, additional, Ruiter, D J, additional, and Muijen, G N P van, additional
- Published
- 1999
- Full Text
- View/download PDF
304. Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
- Author
-
Awada, A, primary, Punt, C J A, additional, Piccart, M J, additional, Tellingen, O Van, additional, Manen, L Van, additional, Kerger, J, additional, Groot, Y, additional, Wanders, J, additional, Verweij, J, additional, and Wagener, D J Th, additional
- Published
- 1999
- Full Text
- View/download PDF
305. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients.
- Author
-
Keilholz, U, primary, Conradt, C, additional, Legha, S S, additional, Khayat, D, additional, Scheibenbogen, C, additional, Thatcher, N, additional, Goey, S H, additional, Gore, M, additional, Dorval, T, additional, Hancock, B, additional, Punt, C J, additional, Dummer, R, additional, Avril, M F, additional, Bröcker, E B, additional, Benhammouda, A, additional, Eggermont, A M, additional, and Pritsch, M, additional
- Published
- 1998
- Full Text
- View/download PDF
306. The use of interferon-α in the treatment of cutaneous melanoma
- Author
-
Punt, C. J. A., primary
- Published
- 1998
- Full Text
- View/download PDF
307. A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study
- Author
-
van Tellingen, O., primary, Punt, C. J. A., additional, Groot, Y., additional, Henrar, R. E. C., additional, Awada, A., additional, Wagener, D. J. T., additional, Piccart, M. J., additional, Schaaf, L. J., additional, Nooijen, W. J., additional, and Beijnen, J. H., additional
- Published
- 1998
- Full Text
- View/download PDF
308. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group.
- Author
-
Keilholz, U, primary, Goey, S H, additional, Punt, C J, additional, Proebstle, T M, additional, Salzmann, R, additional, Scheibenbogen, C, additional, Schadendorf, D, additional, Liénard, D, additional, Enk, A, additional, Dummer, R, additional, Hantich, B, additional, Geueke, A M, additional, and Eggermont, A M, additional
- Published
- 1997
- Full Text
- View/download PDF
309. PCN189 - A Disease Model of Metastatic Colorectal Cancer Including Multiple Treatment Lines
- Author
-
van Rooijen, E.M., Uyl-de Groot, C.A., Punt, C., Koopman, M., and Coupe, V.M.
- Published
- 2013
- Full Text
- View/download PDF
310. Spontaneous fracture of implanted central venous catheters in cancer patients
- Author
-
Punt, C JA, primary, Strijk, S, additional, van der Hoeven, J JM, additional, van de Sluis, R, additional, and Verhagen, C AH, additional
- Published
- 1995
- Full Text
- View/download PDF
311. Abstracts
- Author
-
Derlon, J. M., primary, Petit-taboué, M. C., additional, Dauphin, F., additional, Courtheoux, P., additional, Chapon, F., additional, Creissard, P., additional, Darcel, F., additional, Houtteville, J. P., additional, Kaschten, B., additional, Sadzot, B., additional, Stevenaert, A., additional, Tjuvajev, Juri G., additional, Macapinlac, Homer A., additional, Daghighian, Farhad, additional, Ginos, James Z., additional, Finn, Ronald D., additional, Jiaju Zhang, M. S., additional, Beattie, Bradley, additional, Graham, Martin, additional, Larson, Steven M., additional, Blasberg, Ronald G., additional, Levivier, M., additional, Goldman, S., additional, Pirotte, B., additional, Brucher, J. M., additional, Balériaux, D., additional, Luxen, A., additional, Hildebrand, J., additional, Brotchi, J., additional, Go, K. G., additional, Kamman, R. L., additional, Mooyaart, E. L., additional, Heesters, M. A. A. M., additional, Sijens, P. E., additional, Oudksrk, M., additional, van Dijk, P., additional, Levendag, P. C., additional, Vecht, Ch. J., additional, Metz, R. J., additional, Kennedy, D. N., additional, Rosen, B. R., additional, Hochberg, F. H., additional, Fishman, A. J., additional, Filipek, P. A., additional, Caviness, V. S., additional, Gross, M. W., additional, Weinzierl, F. X., additional, Trappe, A. E., additional, Goebel, W. E., additional, Frank, A. M., additional, Becker, Georg, additional, Krone, Andreas, additional, Schmidt, Karsten, additional, Hofmann, Erich, additional, Bogdahn, Ulrich, additional, Bencsch, H., additional, Fclber, S., additional, Finkenstedt, G., additional, Kremser, C., additional, Sfockhammer, G., additional, Aichner, F., additional, Bogdahn, U., additional, Fröhlich, T., additional, Becker, G., additional, Krone, A., additional, Schlief, R., additional, Schürmann, J., additional, Jachimczak, P., additional, Hofmann, E., additional, Roggendorf, W., additional, Roosen, K., additional, Carapella, C. M., additional, Carpinelli, G., additional, Passalacqua, R., additional, Raus, L., additional, Giannini, M., additional, Mastrostefano, R., additional, Podo, F., additional, Tofani, A., additional, Maslrostefano, R., additional, Mottoles, M., additional, Ferraironi, A., additional, Scelsa, M. G., additional, Oppido, P., additional, Riccio, A., additional, Maini, C. L., additional, Collombier, L., additional, Taillandier, L., additional, Dcbouverie, M., additional, Laurens, M. H., additional, Thouvenot, P., additional, Weber, M., additional, Bertrand, A., additional, Cruickshank, G. S., additional, Patterson, J., additional, Hadley, D., additional, De Witte, Olivier, additional, Hildebrand, Jerzy, additional, Luxen, André, additional, Goldman, Serge, additional, Ernestus, R. -I., additional, Bockhorst, K., additional, Eis, M., additional, Els, T., additional, Hoehn-Berlage, M., additional, Gliese, M., additional, Fründ, R., additional, Geissler, A., additional, Woertgen, C., additional, Holzschuh, M., additional, Hausmann, O., additional, Merlo, A., additional, Jerrnann, E., additional, Uirich, J., additional, Chiquet-Ehrismann, R., additional, Müller, J., additional, Mäcke, H., additional, Gratzl, O., additional, Herholz, K., additional, Ghaemi, M., additional, Würker, M., additional, Pietrzyk, U., additional, Heiss, W. -D., additional, Kotitschke, K., additional, Brandl, M., additional, Tonn, J. C., additional, Haase, A., additional, Muigg, S., additional, Felber, S., additional, Woydt, M., additional, Lanfermann, Heinrich, additional, Heindel, Walter, additional, Kugel, Harald, additional, Erneslus, Ralf -Ingo, additional, Röhn, Gabricle, additional, Lackner, Klaus, additional, Pardo, F. S., additional, Kutke, S., additional, Sorensen, A. G., additional, Mechtler, L. L., additional, Withiam-Lench, S., additional, Shin, K., additional, Klnkel, W. R., additional, Patel, M., additional, Truax, B., additional, Kinkel, P., additional, Mechtler, L., additional, Ricci, M., additional, Pantano, P., additional, Maleci, A., additional, Pierallini, S., additional, Di Stefano, D., additional, Bozzao, L., additional, Cantore, G. P., additional, Röhn, Gabriele, additional, Schröder, R., additional, Ruda, R., additional, Mocellini, C., additional, Soffietti, R., additional, Campana, M., additional, Ropolo, R., additional, Riva, A., additional, de Filippi, P. G., additional, Schiffer, D., additional, Salgado, D., additional, Rodrigues, M., additional, Salgado, L., additional, Fonseca, A. T., additional, Vieira, M. R., additional, Bravo Marques, J. M., additional, Satoh, H., additional, Uozumi, T., additional, Kiya, K., additional, Kurisu, K., additional, Arita, K., additional, Sumida, M., additional, Ikawa, F., additional, Tzuk-Shina, Tz., additional, Gomori, J. M., additional, Rubinstein, R., additional, Lossos, A., additional, Siegal, T., additional, Vaalburg, W., additional, Paans, A. M. J., additional, Willemsen, A. T. M., additional, van Waarde, A., additional, Pruim, J., additional, Visser, G. M., additional, Valentini, S., additional, Ting, Y. L. T., additional, De Rose, R., additional, Chidichimo, G., additional, Corricro, G., additional, van Lcycn-Pilgram, Karin, additional, Erncslus, Ralf -Ingo, additional, Klug, Norfried, additional, van Leyen-Pilgram, K., additional, Klug, N., additional, Neumann, U., additional, Plate, Karl H., additional, Breier, Georg, additional, Millaucr, Birgit, additional, Weich, Herbert A., additional, Ullrich, Axel, additional, Risau, Werner, additional, Roosen, N., additional, Chopra, R. K., additional, Mikkelsen, T., additional, Rosenblum, S. D., additional, Yan, P. S., additional, Knight, R., additional, Windham, J., additional, Rosenblum, M. L., additional, Attanasio, A., additional, Cavalla, P., additional, Chio, A., additional, Giordana, M. T., additional, Migheli, A., additional, Amberger, V., additional, Hensel, T., additional, Schwab, M. E., additional, Cervoni, Luigi, additional, Celli, Paolo, additional, Tarantino, Roberto, additional, Huettner, C., additional, Berweiler, U., additional, Salmon, I., additional, Rorive, S., additional, Rombaut, K., additional, Haot, J., additional, Kiss, R., additional, Maugard-Louboutin, C., additional, Charrier, J., additional, Fayet, G., additional, Sagan, C., additional, Cuillioere, P., additional, Ricolleau, G., additional, Martin, S., additional, Menegalli-Bogeelli, D., additional, Lajat, Y., additional, Resche, F., additional, Molnàr, Péter, additional, Bárdos, Helga, additional, Ádány, Róza, additional, Rogers, J. P., additional, Pilkington, G. J., additional, Pollo, B., additional, Giaccone, G., additional, Allegranza, A., additional, Bugiani, O., additional, Prim, J., additional, Badia, J., additional, Ribas, E., additional, Coello, F., additional, Shezen, E., additional, Abramsky, O., additional, Scerrati, M., additional, Roselli, R., additional, Iacoangeli, M., additional, Pompucci, A., additional, Rossi, G. F., additional, Deeb, Saleh M. Al., additional, Koreich, Osama, additional, Yaqub, Basim, additional, Moutaery, Khalaf R. Al., additional, Marino, S., additional, Vigliani, M. C., additional, Deburghgraeve, V., additional, Gedouin, D., additional, Hassel, M. Ben, additional, Guegan, Y., additional, Jeremic, B., additional, Grujicic, D., additional, Antunovic, V., additional, Matovic, M., additional, Shibamoto, Y., additional, Kallio, Merja, additional, Huhmar, Helena, additional, Kudoh, Ch., additional, Detta, A., additional, Sugiura, K., additional, Hitchcock, E. R., additional, Di Russo, R., additional, Cipriani§, M., additional, Occhipinti, E. M., additional, Conti, E. M. S., additional, Clowegeser, A., additional, Ortler, M., additional, Seiwald, M., additional, Kostron, H., additional, Rajan, B., additional, Ross, G., additional, Lim, C., additional, Ashlcy, S., additional, Goode, D., additional, Traish, D., additional, Brada, M., additional, Sanden, G. A. C. vd, additional, Schouten, L. J., additional, Coebergh, J. W. W., additional, Razenberg, P. P. A., additional, Twijnstra, A., additional, Snilders-Keilholz, A., additional, Voormolen, J. H. C., additional, Hermans, J., additional, Leer, J. W. H., additional, Baylac, F., additional, Dcbouvcrie, M., additional, Anxionnal, R., additional, Bracard, S., additional, Vignand, J. M., additional, Duprcz, A., additional, Winking, M., additional, Böker, D. K., additional, Simmet, T., additional, Rothbart, David, additional, Strugar, John, additional, Balledux, Jeroen, additional, Criscuolo, Gregory R., additional, Jachimczak, Piotr, additional, Blesch, Armin, additional, Heβdörfer, Birgit, additional, Ernestus, Ralf -Ingo, additional, Schröder, Roland, additional, Klug, Norfrid, additional, Krouwer, H. G. J., additional, Duinen, S. G. v., additional, Algra, A., additional, Zentner, J., additional, Wolf, H. K., additional, Ostertun, B., additional, Hufnagel, A., additional, Campos, M. G., additional, Solymosi, L., additional, Schramm, J., additional, Newlands, E. S., additional, O'Reilly, S. M., additional, Brampton, M., additional, Sciolla, R., additional, Seliak, D., additional, Henriksson, R., additional, Bergenheim, A. T., additional, Björk, P., additional, Gunnarsson, P. -O., additional, Hariz, Ml., additional, Grant, R., additional, Collie, D., additional, Gregor, A., additional, Ebmeier, K. P., additional, Jarvis, G., additional, Lander, F., additional, Cull, A., additional, Sellar, R., additional, Thomas, C., additional, Elyan, S., additional, Hines, F., additional, Ashley, S., additional, Stenning, S., additional, Bernstein, J. J., additional, Goldberg, W. J., additional, Roelcke, U., additional, Von Ammon, K., additional, Radu, E. W., additional, Kaech, D., additional, Leenders, K. L., additional, Fitzek, M. M., additional, Aronen, J. Efird, additional, Hochberg, F., additional, Gruber, M., additional, Schmidt, E., additional, Rosen, B., additional, Flschman, A., additional, Pardo, P., additional, Afra, U. M. U., additional, Sipos, L., additional, Slouik, F., additional, Boiardi, A., additional, Salmaggi, A., additional, Pozzi, A., additional, Farinotti, L., additional, Fariselli, L., additional, Silvani, A., additional, Brandes, A., additional, Scelzi, E., additional, Rigon, A., additional, Zampieri, P., additional, Pignataro, M., additional, Amanzo, P. D'., additional, Amista, P., additional, Rotilio, A., additional, Fiorentino, M. V., additional, Thomas, R., additional, Brazil, L., additional, O'Connor, A. M., additional, Salvati, Maurizio, additional, Puzzilli, Fabrizio, additional, Raguso, Michele, additional, Duckworth, R., additional, Rumpling, R., additional, Rottuci, M., additional, Broggi, G., additional, Plrint, N. G., additional, Sabattini, E., additional, Manetto, V., additional, Gambacorta, H., additional, Poggi, S., additional, Pileri, S., additional, Ferracini, R., additional, Plev, D. V., additional, Hopf, N. J., additional, Knosp, E., additional, Bohl, J., additional, Perncczky, A., additional, Catnby, I., additional, Dewitte, O., additional, Pasteels, J. L., additional, Camby, I., additional, Darro, F., additional, Danguy, A., additional, Kiu, M. C., additional, Lai, G. M., additional, Yang, T. S., additional, Ng, K. T., additional, Chen, J. S., additional, Chang, C. N., additional, Leung, W. M., additional, Ho, Y. S., additional, Rychter, M. Deblec, additional, Klimek, A., additional, Liberski, P. P., additional, Karpinaka, A., additional, Krauseneck, P., additional, Schöffel, V., additional, Müller, B., additional, Kreth, F. W., additional, Faist, M., additional, Warnke, P. C., additional, Ostertag, C. B., additional, Nielen, K. M. B. v., additional, Visscr, M. C., additional, Lebrun, C., additional, Lonjon, M., additional, Desjardin, T., additional, Michiels, J. F., additional, Chanalet, Sa. Lagrange J. L., additional, Roche, J. L., additional, Chatel, M., additional, Mastronardi, L., additional, Puzzilli, F., additional, Osman, Farah J., additional, Lunardi, P., additional, Matsutani, M., additional, Ushio, Y., additional, Takakura, K., additional, Menten, Johan, additional, Hamers, Han, additional, Ribot, Jacques, additional, Dom, René, additional, Tcepen, Hans, additional, Weidner, N., additional, Naujocks, G., additional, van Roost, D., additional, Wiestler, O. D., additional, Kuncz, A., additional, Nieder, C., additional, Setzel-Sesterhein, M., additional, Niewald, M., additional, Schnabel, I., additional, O'Neill, K. S., additional, Kitchen, N. D., additional, Wilkins, P. R., additional, Marsh, H. T., additional, Pierce, E., additional, Doshi, R., additional, Deane, R., additional, Previtali, S., additional, Quattrini, A., additional, Nemni, R., additional, Ducati, A., additional, Wrabetz, L., additional, Canal, N., additional, Punt, C. J. A., additional, Stamatakis, L., additional, Giroux, B., additional, Rutten, E., additional, Quigley, Matthew R., additional, Beth Sargent, P. A. -C., additional, Flores, Nicholas, additional, Simon, Sheryl, additional, Maroon, Joseph C., additional, Rocca, A. A., additional, Gervasoni, C., additional, Castagna, A., additional, Picozzi, P., additional, Giugni, E., additional, Tonnarelli, G. P., additional, Mangili, F., additional, Truci, G., additional, Giovanelli, M., additional, Sachsenheimer, W., additional, Bimmler, T., additional, Eiter, H. Rhomberg W., additional, Obwegesser, A., additional, Steilen, H., additional, Henn, W., additional, Moringlane, J. R., additional, Kolles, H., additional, Feiden, W., additional, Zang, K. D., additional, Sleudel, W. I., additional, Steinbrecher, Andreas, additional, Schabet, Martin, additional, Heb, Clemens, additional, Bamberg, Michael, additional, Dichgans, Johannes, additional, Stragliotto, G., additional, Delattre, J. Y., additional, Poisson, M., additional, Tosatto, L., additional, D'Amanzo, P., additional, Menicucci, N., additional, Mingrino, S., additional, Steudel, W. I., additional, Feld, R., additional, Maire, J. Ph., additional, Caudry, M., additional, Guerin, J., additional, Celerier, D., additional, Salem, N., additional, Demeaux, H., additional, Fahregat, J. F., additional, Kusak, M. E., additional, Bucno, A., additional, Albisua, J., additional, Jerez, P., additional, Sarasa, J. L., additional, Garefa, R., additional, de Campos, J. M., additional, Bueno, A., additional, García-Delgado, R., additional, García-Sola, R., additional, Lantsov, A. A., additional, Shustova, T. I., additional, Lcnartz, D., additional, Wellenreuther, R., additional, von Deirnling, A., additional, Köning, W., additional, Menzel, J., additional, Scarpa, S., additional, Manna, A., additional, Reale, M. G., additional, Oppido, P. A., additional, Frati, L., additional, Valery, C. A., additional, Ichen, M., additional, Foncin, J. P., additional, Soubrane, C., additional, Khayat, D., additional, Philippon, J., additional, Vaz, R., additional, Cruz, C., additional, Weis, S., additional, Protopapa, D., additional, März, R., additional, Winkler, P. A., additional, Reulen, H. J., additional, Bise, K., additional, Beuls, E., additional, Berg, J., additional, Deinsberger, W., additional, Samii, M., additional, Darrouzet, V., additional, Guérin, J., additional, Trouette, R., additional, Causse, N., additional, Bébéar, J. P., additional, Parker, F., additional, Vallee, J. N., additional, Carlier, R., additional, Zerah, M., additional, Lacroix-Jousselin, C., additional, Piepmeier, Joseph M., additional, Kveton, John, additional, Czibulka, Agnes, additional, Tigliev, G. S., additional, Chernov, M. P., additional, Maslova, L. N., additional, Valdueza, José M., additional, Jänisch, Werner, additional, Bock, Alexander, additional, Harms, Lutz, additional, Bessell, E. M., additional, Graus, F., additional, Punt, J., additional, Firth, J., additional, Hope, T., additional, Koriech, Osama, additional, Al Deeb, Saleh, additional, Al Moutaery, Khalaf, additional, Yaqub, B., additional, Franzini, A., additional, Goldbrunner, R., additional, Warmuth-Metz, M., additional, Paulus, W., additional, Tonn, J. -Ch., additional, Strik, I. I., additional, Markert, C., additional, Pflughaupt, K. -W., additional, O'Neill, B. P., additional, Dinapoli, R. P., additional, Voges, J., additional, Sturm, V., additional, Deuß, U., additional, Traud, C., additional, Treuer, H., additional, Lehrke, R., additional, Kim, D. G., additional, Müller, R. P., additional, Alexandrov, Yu. S., additional, Moutaery, K., additional, Aabed, M., additional, Koreich, O., additional, Ross, G. M., additional, Ford, D., additional, Schmeets, I. L. O., additional, Jager, J. J., additional, Pannebakker, M. A. G., additional, de Jong, J. M. A., additional, van Lindert, E., additional, Kitz, K., additional, Blond, S., additional, Dubois, F., additional, Assaker, R., additional, Baranzelli, M. C., additional, Sleiman, M., additional, Pruvo, J. P., additional, Coche-Dequeant, B., additional, Sano, K., additional, PetriČ-Grabnar, G., additional, Jereb, B., additional, Župančič, N., additional, Koršič, M., additional, Rainov, N. G., additional, Burkert, W., additional, Ushio, Yukitaka, additional, Kochi, Masato, additional, Itoyama, Youichi, additional, García, R., additional, Ferrando, L., additional, Hoang-Xuan, K., additional, Sanson, M., additional, Merel, P., additional, Delattre, O., additional, Thomas, G., additional, Haritz, D., additional, Obersen, B., additional, Grochulla, F., additional, Gabel, D., additional, Haselsberger, K., additional, Radner, H., additional, Pendl, G., additional, Laing, R. W., additional, Warrington, A. P., additional, Nowak, P. J. C. M., additional, Kolkman-Deurloo, I. K. K., additional, Visser, A. G., additional, Berge, Hv. d., additional, Niël, C. G. J. H., additional, Bergström, P., additional, Hariz, M., additional, Löfroth, P. -O., additional, Bergenheim, T., additional, Cortet-rudelli, C., additional, Dewailly, D., additional, Coche-dequeant, B., additional, Castelain, B., additional, Dinapoli, R., additional, Shaw, E., additional, Coffey, R., additional, Earle, J., additional, Foote, R., additional, Schomberg, P., additional, Gorman, D., additional, Girard, N., additional, Courel, M. N., additional, Delpech, B., additional, Friehs, G. M., additional, Schröttner, O., additional, Pötter, R., additional, hawliczek, R., additional, Sperveslage, P., additional, Prott, F. J., additional, Wachter, S., additional, Dieckmann, K., additional, Bauer, B., additional, Jund, R., additional, Zimmermann, F., additional, Feldmann, H. J., additional, Kneschaurek, P., additional, Molls, M., additional, Lederman, G., additional, Lowry, J., additional, Wertheim, S., additional, Voulsinas, L., additional, Fine, M., additional, Voutsinas, I., additional, Qian, G., additional, Rashid, H., additional, Montemaggi, P., additional, Trignani, R., additional, West, C., additional, Grand, W., additional, Sibata, C., additional, Guerrero, D., additional, James, N., additional, Bramer, R., additional, Pahlke, H., additional, Banik, N., additional, Hövels, M., additional, Bernsen, H. J. J. A., additional, Rijken, P. F. J. W., additional, Van der Sanden, B. P. J., additional, Hagemeier, N. E. M., additional, Van der Kogel, A. J., additional, Koehler, P. J., additional, Verbiest, H., additional, Jager, J., additional, McIlwrath, A., additional, Brown, R., additional, Mottolesb, C., additional, Pierre'Kahn, A., additional, Croux, M., additional, Marchai, J., additional, Delhemes, P., additional, Tremoulet, M., additional, Stilhart, B., additional, Chazai, J., additional, Caillaud, P., additional, Ravon, R., additional, Passacha, J., additional, Bouffet, E., additional, Dirven, C. M. F., additional, Mooy, J. J. A., additional, Molenaar, W. M., additional, Lewandowicz, G. M., additional, Grant, N., additional, Harkness, W., additional, Hayward, R., additional, Thomas, D. G. T., additional, Darling, J. L., additional, Delepine, N., additional, Subovici, I. I., additional, Cornille, B., additional, Markowska, S., additional, Alkallaf, JC. Desbois, additional, KühI, J., additional, Niethammer, D., additional, Spaar, H. J., additional, Gnekow, A., additional, Havers, W., additional, Berthold, F., additional, Graf, N., additional, Lampert, F., additional, Maass, E., additional, Mertens, R., additional, Schöck, V., additional, Aguzzi, A., additional, Boukhny, A., additional, Smirtukov, S., additional, Prityko, A., additional, Hoiodov, B., additional, Geludkova, O., additional, Nikanorov, A., additional, Levin, P., additional, D'haen, B., additional, Van Calenbergh, F., additional, Casaer, P., additional, Dom, R., additional, Menten, J., additional, Goffin, J., additional, Plets, C., additional, Hertel, A., additional, Hernaiz, P., additional, Seipp, C., additional, Siegler, K., additional, Baum, R. P., additional, Maul, F. D., additional, Schwabe, D., additional, Jacobi, G., additional, Kornhuber, B., additional, Hör, G., additional, Merzak, A., additional, Rooprai, H. K., additional, Bullock, P., additional, van Domburg, P. H. M. F., additional, Wesseling, P., additional, Thijssen, H. O. M., additional, Wolff, J. E. A., additional, Boos, J., additional, Krähling, K. H., additional, Gressner-Brocks, V., additional, Jürgens, H., additional, Schlegel, J., additional, Scherthan, H., additional, Arens, N., additional, Stumm, Gabi, additional, Kiessling, Marika, additional, Koochekpour, S., additional, Reifenberger, G., additional, Reifenberger, J., additional, Liu, L., additional, James, C. D., additional, Wechsler, W., additional, Collins, V. P., additional, Fabel-Schulte, Klaus, additional, Jachimczak, Plotr, additional, Heßdörfer, Birgitt, additional, Baur, Inge, additional, Schlingensiepen, Karl -Hermann, additional, Brysch, Wolgang, additional, Blesch, A., additional, Bosserhoff, A. K., additional, Apfel, R., additional, Lottspeich, F., additional, Büttner, R., additional, Cece, R., additional, Barajon, I., additional, Tazzari, S., additional, Cavaletti, G., additional, Torri-Tarelli, L., additional, Tredici, G., additional, Hecht, B., additional, Turc-Carel, C., additional, Atllas, R., additional, Gaudray, P., additional, Gioanni, J., additional, Hecht, F., additional, Rey, J. A., additional, Bello, M. J., additional, Parent, M., additional, Gosselin, P., additional, Christiaens, J. L., additional, Schaudies, J. R., additional, Janka, M., additional, Fischer, U., additional, Meese, E., additional, Remmelink, M., additional, Cras, P., additional, Bensadoun, R. J., additional, Frenay, M., additional, Formento, J. L., additional, Milano, G., additional, Lagrange, J. L., additional, Grellier, P., additional, Lee, J. -Y., additional, Riese, H. -H., additional, Cervós-Navarro, J., additional, Reutter, W., additional, Lippitz, B., additional, Scheitinger, C., additional, Scholz, M., additional, Weis, J., additional, Gilsbach, J. M., additional, Füzesi, L., additional, Li, Y. J., additional, Hamelin, R., additional, Van de Kelft, Erik, additional, Dams, Erna, additional, Martin, Jean -Jacques, additional, Willems, Patrick, additional, Erdmann, J., additional, Wurm, R. E., additional, Sardell, S., additional, Graham, J. D., additional, Kuratsu, Jun -ichi, additional, Aichholzer, M., additional, Rössler, K., additional, Alesch, F., additional, Ertl, A., additional, Sorensen, P. S., additional, Helweg-Larsen, S., additional, Mourldsen, H., additional, Hansen, H. H., additional, El Sharoum, S. Y., additional, Berfelo, M. W., additional, Theunissen, P. H. M. H., additional, Fedorcsák, I., additional, Nyáry, I., additional, Osztie, É., additional, Horvath, Á., additional, Kontra, G., additional, Burgoni-chuzel, J., additional, Paquis, P., additional, Hansen, SW., additional, Sørensen, PS., additional, Morche, M., additional, Lagerwaard, F. J., additional, Eijkenboom, W. M. H., additional, Schmilz, P. I. M., additional, Lentzsch, S., additional, Weber, F., additional, Franke, J., additional, Dörken, B., additional, Schettini, G., additional, Qasho, R., additional, Garabello, D., additional, Sales, S., additional, De Lucchi, R., additional, Vasario, E., additional, Muracciole, X., additional, Régis, J., additional, Manera, L., additional, Peragut, J. C., additional, Juin, P., additional, Sedan, R., additional, Walter, K., additional, Schnabel, K., additional, Niewald, N., additional, Nestle, U., additional, Berberich, W., additional, Oschmann, P., additional, Theißen, R. D., additional, Reuner, K. H., additional, Kaps, M., additional, Dorndorf, W., additional, Martin, K. K., additional, Akinwunmi, J., additional, Kennedy, A., additional, Linke, A., additional, Ognjenovic, N., additional, Svadovsky, A. I., additional, Peresedov, V. V., additional, Bulakov, A. A., additional, Butyalko, M. Y., additional, Zhirnova, I. G., additional, Labunsky, D. A., additional, Gnazdizky, V. V., additional, Gannushkina, I. V., additional, Taphoorn, M. J. B., additional, Potman, R., additional, Barkhof, F., additional, Weerts, J. G., additional, Karim, A. B. M. F., additional, Heimans, J. J., additional, van de Pol, M., additional, van Aalst, V. C., additional, Wilmink, J. T., additional, van der Sande, J. J., additional, Boogerd, W., additional, Kröger, R., additional, Jäger, A., additional, Wismeth, C., additional, Dekant, A., additional, Brysch, W., additional, Schlingensiepen, K. H., additional, Pirolte, B., additional, Cool, V., additional, Gérard, C., additional, Dargent, J. L., additional, Velu, T., additional, Herrlinger, U., additional, Schabet, M., additional, Ohneseit, P., additional, Buchholz, R., additional, Zhu, Jianhong, additional, Reszka, Regina, additional, Weber, Friedrich, additional, Walther, Wolfgang, additional, Zhang, L. I., additional, Brock, Mario, additional, Rock, J. P., additional, Zeng, H., additional, Feng, J., additional, Fenstermacher, J. D., additional, Gabizon, A., additional, Beljanski, M., additional, Crochet, S., additional, Zackrisson, B., additional, Elfverson, J., additional, Butti, G., additional, Baetta, R., additional, Magrassi, L., additional, De Renzis, M. R., additional, Soma, M. R., additional, Davegna, C., additional, Pezzotta, S., additional, Paoletti, R., additional, Fumagalli, R., additional, Infuso, L., additional, Sankar, A. A., additional, Defer, G. -L., additional, Brugières, P., additional, Gray, F., additional, Chomienne, C., additional, Poirier, J., additional, Degos, L., additional, Degos, J. D., additional, Colombo, Bruno M., additional, DiDonato, Stefano, additional, Finocchiaro, Gaetano, additional, Hebeda, K. M., additional, Sterenborg, H. J. C. M., additional, Saarnak, A. E., additional, Wolbers, J. G., additional, van Gemert, M. J. C., additional, Kaaijk, P., additional, Troost, D., additional, Leenstra, S., additional, Das, P. K., additional, Bosch, D. A., additional, Hochleitner, B. W., additional, Obwegeser, A., additional, Vooys, W., additional, de Gast, G. C., additional, Marx, J. J. M., additional, Menovsky, T., additional, Beek, J. F., additional, Schirrmacher, V., additional, Schmitz, A., additional, Eis-Hübinger, A. M., additional, Piepmeier, p. h., additional, Pedersen, Patricia, additional, Greer, Charles, additional, Shih, Tommy, additional, Elrifal, Amr, additional, Rothfus, William, additional, Rohertson, L., additional, Rampling, R., additional, Whoteley, T. L., additional, Piumb, J. A., additional, Kerr, D. J., additional, Falina, P. A., additional, Crossan, I. M., additional, Ho, K. L., additional, Ruchoux, M. M., additional, Vincent, S., additional, Jonca, F., additional, Plouet, J., additional, Lecomte, M., additional, Samid, D., additional, Thibault, A., additional, Ram, Z., additional, Oldfield, E. H., additional, Myers, C. E., additional, Reed, E., additional, Shoshan, Y., additional, Siegal, Tz., additional, Stockhammer, G., additional, Rosenblum, M., additional, Lieberman, F., additional, Terzis, A. J. A., additional, Bjerkvig, R., additional, Laerum, O. D., additional, Arnold, H., additional, Figg, W. D., additional, Flux, G., additional, Chittenden, S., additional, Doshi, P., additional, Bignor, D., additional, Zalutsky, M., additional, Tjuvajev, Juri, additional, Kaplitt, Michael, additional, Desai, Revathi, additional, Bradley, M. S., additional, Bettie, B. S., additional, Gansbacher, Bernd, additional, Blasberg, Ronald, additional, Haugland, H. K., additional, Saraste, J., additional, Rooseni, K., additional, Vincent, A. J. P. E., additional, Avezaat, C. J. J., additional, Bout, A., additional, Noteboom, J. L., additional, Vecht, C. h., additional, Valerio, D., additional, Hoogerbrugge, P. M., additional, Reszka, R., additional, Zhu, J., additional, Walther, W., additional, List, J., additional, Schulz, W., additional, Sterenborg, I. I. J. C. M., additional, Kamphorst, W., additional, van Alplien, H. A. M., additional, Salander, P., additional, Laing, R., additional, Schmidt, B., additional, Grau, G., additional, Bohnstedt, T., additional, Frydrych, A., additional, Franz, K., additional, Lorenz, R., additional, Berti, F., additional, Paccagnella, A., additional, van Deventer, P. L., additional, Dellemijn, P. L. I., additional, van den Bent, M. J., additional, Kansen, P. J., additional, Petruccioli, N. G., additional, Cavalletti, E., additional, Kiburg, B., additional, Müller, L. J., additional, Moorer-van Delft, C. M., additional, Boer, H. H., additional, Pace, A., additional, Bove, L., additional, Pietrangeli, A., additional, Innocenti, P., additional, Aloe, A., additional, Nardi, M., additional, Jandolo, B., additional, Kellie, S. J., additional, De Graaf, S. S. N., additional, Bloemhof, H., additional, Roebuck, D., additional, Dalla, Pozza L., additional, Uges, D. D. R., additional, Johnston, I., additional, Besser, M., additional, Chaseling, R. A., additional, Koeppen, S., additional, Gründemann, S., additional, Nitschke, M., additional, Vieregge, P., additional, Reusche, E., additional, Rob, P., additional, Kömpf, D., additional, Postma, T. J., additional, Vermorken, J. B., additional, Rampling, R. P., additional, Dunlop, D. J., additional, Steward, M. S., additional, Campbell, S. M., additional, Roy, S., additional, Hilkens, P. H. E., additional, Verweij, J., additional, van Putten, W. L. J., additional, Moll, J. W. B., additional, van der Burg, M. E. L., additional, Planting, A. S. T., additional, Wondrusch, E., additional, Zifko, U., additional, Drlicek, M., additional, Liszka, U., additional, Grisold, W., additional, Fazeny, B., additional, Dittrich, Ch., additional, Verschuuren, Jan J., additional, Meneses, Patricio I., additional, Rosenfeld, Myrna R., additional, Kaplitt, Michael G., additional, Posner, Jerome B., additional, Dalmau, Josep, additional, Sillevis Smitt, P. A. E., additional, Manley, G., additional, Posner, J. B., additional, Bogliun, G., additional, Margorati, L., additional, Bianchi, G., additional, Liska, U., additional, Casati, B., additional, Kolig, C., additional, Grisold, H., additional, Reñe, R., additional, Uchuya, M., additional, Valldeoriola, F., additional, Benedetti de Cosentiro, C., additional, Ortale, D., additional, Martinez, R., additional, Lambre, J., additional, Cagnolati, S., additional, Vinai, C., additional, Forno, M. G., additional, Luksch, R., additional, Confalonieri, P., additional, Scholz, J., additional, Pfeiffer, G., additional, Netzer, J., additional, Hansen, Ch., additional, Eggers, Ch., additional, Hagel, Ch., additional, Kunze, K., additional, Rosenblum, Marc K., additional, and Lieberman, Frank S., additional
- Published
- 1994
- Full Text
- View/download PDF
312. Reproducibility and biological basis of in vivo T2* magnetic resonance imaging of liver metastasis of colorectal cancer.
- Author
-
ter Voert, E. G. W., Heijmen, L., Wilt, J. H. W., Bussink, J., Punt, C. J. A., Laarhoven, H. W. M., and Heerschap, A.
- Abstract
In this study, the reproducibility of [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
313. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach.
- Author
-
Heijmen, L., Punt, C., Voert, E., Geus-Oei, L., Heerschap, A., Bussink, J., Sweep, C., Zerbi, V., Oyen, W., Span, P., Boerman, O., and Laarhoven, H.
- Subjects
ANIMAL experimentation ,ANTIMETABOLITES ,COMBINATION drug therapy ,COLON tumors ,STATISTICAL correlation ,ENZYME-linked immunosorbent assay ,IMMUNOHISTOCHEMISTRY ,MAGNETIC resonance imaging ,METASTASIS ,MICE ,ORAL drug administration ,HEALTH outcome assessment ,RECTUM tumors ,RESEARCH funding ,T-test (Statistics) ,POSITRON emission tomography ,OXALIPLATIN ,TREATMENT effectiveness ,BEVACIZUMAB ,DISEASE progression ,TREATMENT duration ,DATA analysis software - Abstract
Clinical studies have shown that bevacizumab beyond progression to first line therapy is beneficial for overall survival in advanced stage colorectal cancer. We studied the utility of several functional imaging modalities to assess the efficacy of bevacizumab beyond progression (BBP). All BALB/c mice with s.c. LS174T xenografts were treated with capecitabine, oxaliplatin and bevacizumab combination therapy. Tumor volume was assessed using caliper measurements. Increase of 1.5 times the initial volume on two subsequent measurements, was considered progression. In half of the mice bevacizumab treatment was continued ( n = 13) after progressive disease was established, while the others received saline injections ( n = 12). Within 3 days after progression, multi-modal imaging was performed using FDG-PET, diffusion weighted imaging, T2* and dynamic contrast enhanced MRI. Measurements were repeated 7 and 10 days after the first measurements. Afterwards, tumors were analyzed for expression of carbonic anhydrase IX, glucose transporter 1, 9 F1 to stain the vasculature and Ki67 to assess proliferation. In the BBP group tumor growth after progression was reduced compared to the control group ( p < 0.01). FDG-PET showed a trend towards lower FDG uptake in the BBP group ( p = 0.08). DWI, T2* and DCE-MRI parameters were not significantly different between both groups. The immunohistochemical analyses showed higher CAIX-positive fraction ( p < 0.01) and lower Ki67 expression ( p = 0.06) in the BBP group. The relative vascular area was significantly lower in the BBP group ( p = 0.03). GLUT-1 expression and vascular density did not significantly differ between both groups. Bevacizumab after progression resulted in significant changes in the tumor proliferation and microenvironment compared to discontinuation of bevacizumab. FDG-PET may be sensitive to BBP-induced effects. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
314. Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer.
- Author
-
Sloothaak, D. A. M., Geijsen, D. E., van Leersum, N. J., Punt, C. J. A., Buskens, C. J., Bemelman, W. A., and Tanis, P. J.
- Subjects
RECTAL cancer treatment ,RECTAL surgery ,ADJUVANT treatment of cancer ,CANCER radiotherapy ,CANCER chemotherapy ,HEALTH outcome assessment - Abstract
Background Neoadjuvant chemoradiotherapy ( CRT) has been proven to increase local control in rectal cancer, but the optimal interval between CRT and surgery is still unclear. The purpose of this study was to analyse the influence of variations in clinical practice regarding timing of surgery on pathological response at a population level. Methods All evaluable patients who underwent preoperative CRT for rectal cancer between 2009 and 2011 were selected from the Dutch Surgical Colorectal Audit. The interval between radiotherapy and surgery was calculated from the start of radiotherapy. The primary endpoint was pathological complete response ( pCR; pathological status after chemoradiotherapy (yp) T0 N0). Results A total of 1593 patients were included. The median interval between radiotherapy and surgery was 14 (range 6-85, interquartile range 12-16) weeks. Outcome measures were calculated for intervals of less than 13 weeks (312 patients), 13-14 weeks (511 patients), 15-16 weeks (406 patients) and more than 16 weeks (364 patients). Age, tumour location and R0 resection rate were distributed equally between the four groups; significant differences were found for clinical tumour category ( cT4: 17·3, 18·4, 24·5 and 26·6 per cent respectively; P = 0·010) and clinical metastasis category ( cM1: 4·4, 4·8, 8·9 and 14·9 per cent respectively; P < 0·001). Resection 15-16 weeks after the start of CRT resulted in the highest pCR rate (18·0 per cent; P = 0·013), with an independent association (hazard ratio 1·63, 95 per cent confidence interval 1·20 to 2·23). Results for secondary endpoints in the group with an interval of 15-16 weeks were: tumour downstaging, 55·2 per cent ( P = 0·165); nodal downstaging, 58·6 per cent ( P = 0·036); and (near)-complete response, 23·2 per cent ( P = 0·124). Conclusion Delaying surgery until the 15th or 16th week after the start of CRT (10-11 weeks from the end of CRT) seemed to result in the highest chance of a pCR. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
315. HIGH DOSE BOLUS THERAPY WITH IL-2 AND αIFN FOR METASTATIC MELANOMA
- Author
-
Eggermont, A. M. M., primary, Goey, S. H., additional, de Mulder, P., additional, Punt, C. J. A., additional, Bolhuis, R. L. H., additional, and Stoter, G., additional
- Published
- 1992
- Full Text
- View/download PDF
316. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004).
- Author
-
Ruers, T., Punt, C., Van Coevorden, F., Pierie, J. P. E. N., Borel-Rinkes, I., Ledermann, J. A., Poston, G., Bechstein, W., Lentz, M. A., Mauer, M., Van Cutsem, E., Lutz, M. P., and Nordlinger, B.
- Subjects
- *
CATHETER ablation , *COLON cancer treatment , *METASTASIS , *CLINICAL trials , *LIVER cancer , *COMBINED modality therapy , *CANCER invasiveness - Abstract
Background This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. Methods This phase II study, originally started as a phase III design, randomly assigned 119 patients with non-resectable colorectal liver metastases between systemic treatment (n = 59) or systemic treatment plus RFA ( ± resection) (n = 60). Primary objective was a 30-month overall survival (OS) rate >38% for the combined treatment group. Results The primary end point was met, 30-month OS rate was 61.7% [95% confidence interval (CI) 48.2–73.9] for combined treatment. However, 30-month OS for systemic treatment was 57.6% (95% CI 44.1–70.4), higher than anticipated. Median OS was 45.3 for combined treatment and 40.5 months for systemic treatment (P = 0.22). PFS rate at 3 years for combined treatment was 27.6% compared with 10.6% for systemic treatment only (hazard ratio = 0.63, 95% CI 0.42–0.95, P = 0.025). Median progression-free survival (PFS) was 16.8 months (95% CI 11.7–22.1) and 9.9 months (95% CI 9.3–13.7), respectively. Conclusions This is the first randomized study on the efficacy of RFA. The study met the primary end point on 30-month OS; however, the results in the control arm were in the same range. RFA plus systemic treatment resulted in significant longer PFS. At present, the ultimate effect of RFA on OS remains uncertain. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
317. Assessment of Blood Hemodynamics by USPIO-Induced R1 Changes in MRI of Murine Colon Carcinoma.
- Author
-
Gambarota, Giulio, Laarhoven, H., Philippens, M., Peeters, W., Rijken, P., Kogel, A., Punt, C., and Heerschap, A.
- Abstract
The objective of this study is to assess whether ultrasmall superparamagnetic iron oxide (USPIO)-induced changes of the water proton longitudinal relaxation rate ( R
1 ) provide a means to assess blood hemodynamics of tumors. Two types of murine colon tumors (C26a and C38) were investigated prior to and following administration of USPIO blood-pool contrast agent with fast R1 measurements. In a subpopulation of mice, R1 was measured following administration of hydralazine, a well-known blood hemodynamic modifier. USPIO-induced R1 increase in C38 tumors (Δ R1 = 0.072 ± 0.0081 s−1 ) was significantly larger than in C26a tumors (Δ R1 = 0.032 ± 0.0018 s−1 , N = 9, t test, P < 0.001). This was in agreement with the immunohistochemical data that showed higher values of relative vascular area (RVA) in C38 tumors than in C26a tumors (RVA = 0.059 ± 0.015 vs. 0.020 ± 0.011; P < 0.05). Following administration of hydralazine, a decrease in R1 value was observed. This was consistent with the vasoconstriction induced by the steal effect mechanism. In conclusion, R1 changes induced by USPIO are sensitive to tumor vascular morphology and to blood hemodynamics. Thus, R1 measurements following USPIO administration can give novel insight into the effects of blood hemodynamic modifiers, non-invasively and with a high temporal resolution. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
318. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer.
- Author
-
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M. A., Mitchell, E., Miller, M. C., Doyle, G. V., Tissing, H., Terstappen, L. W. M. M., and Meropol, N. J.
- Subjects
- *
CANCER cells , *COLON cancer , *CANCER patients , *CANCER prognosis , *METASTASIS - Abstract
Background: We demonstrated that circulating tumor cell (CTC) number at baseline and follow-up is an independent prognostic factor in metastatic colorectal cancer (mCRC). This analysis was undertaken to explore whether patient and treatment characteristics impact the prognostic value of CTCs. [ABSTRACT FROM PUBLISHER]
- Published
- 2009
- Full Text
- View/download PDF
319. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of...
- Author
-
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A, Bottomley, Andrew, and Coens, Corneel
- Published
- 2009
- Full Text
- View/download PDF
320. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients.
- Author
-
Vries, I. J. M., Bernsen, M. R., van Geloof, W. L., Scharenborg, N. M., Lesterhuis, W. J., Rombout, P. D. M., Van Muijen, G. N. P., Figdor, C. G., Punt, C. J. A., Ruiter, D. J., and Adema, G. J.
- Subjects
T cells ,CANCER treatment ,LYMPHOCYTES ,DENDRITIC cells ,NEUROENDOCRINE tumors ,TUMORS ,IMMUNE response ,MAJOR histocompatibility complex ,MELANOMA ,PATIENTS - Abstract
Application of tetrameric MHC class I-peptide complexes has significantly improved the monitoring of antigen-specific T cell immune responses in mouse models as well as in clinical studies. Especially MHC class I tetramer analysis of tumor-specific T cells in suspension or on thick vibratome sections from viable tissue has been proven extremely useful. Using the well-characterized mouse tyrosinase-related-protein-2 specific cytotoxic T cell (CTL) clone LP9, we now developed a method that allows for specific identification of T cells with MHC class I tetramers in 8 μm thick, chemically fixed cryosections. The protocol was validated in a murine influenza virus-infection model. Moreover, analysis of delayed type hypersensitivity (DTH) skin biopsies from melanoma patients vaccinated with peptide-loaded mature dendritic cells, revealed the presence and location of anti-tumor CTLs. The specificity of the CTLs detected in situ correlated with both the DTH challenge specificity and reactivity of cell suspensions derived from the same biopsies. Collectively, our data demonstrate that in situ MHC class I tetramer staining provides a valuable tool to reveal the presence and anatomical location of specific CTLs in frozen tissue following immune-based treatment strategies in cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
321. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
- Author
-
van Laarhoven, H. W. M., Klomp, D. W. J., Rijpkema, M., Kamm, Y. L. M., Wagener, D. J. Th., Barentsz, J. O., Punt, C. J. A., and Heerschap, A.
- Abstract
Systemic chemotherapy is effective in only a subset of patients with metastasized colorectal cancer. Therefore, early selection of patients who are most likely to benefit from chemotherapy is desirable. Response to treatment may be determined by the delivery of the drug to the tumor, retention of the drug in the tumor and by the amount of intracellular uptake, metabolic activation and catabolism, as well as other factors. The first aim of this study was to investigate the predictive value of DCE-MRI with the contrast agent Gd-DTPA for tumor response to first-line chemotherapy in patients with liver metastases of colorectal cancer. The second aim was to investigate the predictive value of 5-fluorouracil (FU) uptake, retention and catabolism as measured by localized
19 F MRS for tumor response to FU therapy. Since FU uptake, retention and metabolism may depend on tumor vascularization, the relationship between19 F MRS and the DCE-MRI parameters kep , Ktrans and ve was also examined (). In this study, 37 patients were included. The kinetic parameters of DCE-MRI, kep , Ktrans and ve , before start of treatment did not predict tumor response after 2 months, suggesting that the delivery of chemotherapy by tumor vasculature is not a major factor determining response in first-line treatment. No evident correlations between19 F MRS parameters and tumor response were found. This suggests that in liver metastases that are not selected on the basis of their tumor diameter, FU uptake and catabolism are not limiting factors for response. The transfer constant Ktrans , as measured by DCE-MRI before start of treatment, was negatively correlated with FU half-life in the liver metastases, which suggests that, in metastases with a larger tumor blood flow or permeability surface area product, FU is rapidly washed out from the tumor. Copyright © 2006 John Wiley & Sons, Ltd. [ABSTRACT FROM AUTHOR]- Published
- 2007
- Full Text
- View/download PDF
322. Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
- Author
-
Punt, C., Mulder, P., Burghouts, J., Wagener, D., Punt, C J, de Mulder, P H, Burghouts, J T, and Wagener, D J
- Abstract
A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients. Therefore, designed a trial of high-dose continuous-infusion 5FU, oral leucovorin (LV), and alpha IFN in this group of patients. Because this combination has not previously been tested and severe toxicity has been reported for 5FU and alpha IFN combination therapy, we conducted a phase I trial in which 11 patients presenting with previously untreated metastatic colorectal cancer were treated with escalating doses of alpha IFN together with fixed doses of 5FU and LV. WHO grade III toxicity consisting mainly of oral mucositis was noted in four patients. No grade IV toxicity occurred. Although alpha IFN may enhance the toxicity of 5FU, the toxicity of this regimen remained manageable. Three partial responses were noted. [ABSTRACT FROM AUTHOR]
- Published
- 1992
- Full Text
- View/download PDF
323. Continuous infusion of high-dose 5-fluorouracil in combination with leucovorin and recombinant interferon-alpha-2b in patients with advanced colorectal cancer. A Multicenter Phase II study.
- Author
-
Punt, Cornelis J. A., Burghouts, Jos Th. M., Croles, Jelle J., van Liessum, Peter A., de Mulder, Pieter H. M., Kamm, Yvonne, Punt, C J, Burghouts, J T, Croles, J J, van Liessum, P A, de Mulder, P H, and Kamm, Y
- Published
- 1993
- Full Text
- View/download PDF
324. New drugs in the treatment of colorectal carcinoma.
- Author
-
Punt, Cornelis J. A. and Punt, C J
- Published
- 1998
- Full Text
- View/download PDF
325. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.
- Author
-
Punt, CJ, Voest, EE, Tueni, E, Van Oosterom, AT, Backx, A, De Mulder, PH, Hecquet, B, Lucas, C, Gerard, B, Bleiberg, H, Punt, C J, Voest, E E, Van Oosterom, A T, and De Mulder, P H
- Published
- 1997
- Full Text
- View/download PDF
326. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
- Author
-
Punt, CJA, van Herpen, CML, Jansen, RLH, Vreugdenhil, G, Muller, EW, de Mulder, PHM, Punt, C J, van Herpen, C M, Jansen, R L, Muller, E W, and de Mulder, P H
- Published
- 1997
- Full Text
- View/download PDF
327. Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma.
- Author
-
Kruit, WHJ, Punt, CJA, Goey, SH, de Mulder, PHM, Gratama, JW, Eggermont, AMM, Bolhuis, RLH, Stoter, G, Kruit, W H, Punt, C J, Goey, S H, de Mulder, P H, Gratama, J W, Eggermont, A M, and Bolhuis, R L
- Published
- 1996
- Full Text
- View/download PDF
328. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
- Author
-
Goey, SH, Eggermont, AMM, Punt, CJA, Slingerland, R, Gratama, JW, Oosterom, R, Oskam, R, Bolhuis, RLH, Stoter, G, Goey, S H, Eggermont, A M, Punt, C J, Gratama, J W, and Bolhuis, R L
- Published
- 1995
- Full Text
- View/download PDF
329. Tyrosine protein kinase activity in normal and leukaemic human blood cells.
- Author
-
Punt, C. J. A., Rijksen, G., Vlug, A. M. C., Dekker, A. W., and Staal, G. E. J.
- Published
- 1989
- Full Text
- View/download PDF
330. RE: Effects of adjuvant chemotherapy on recurrence, survival and quality of life in stage II colon cancer patients: a 24-month follow-up.
- Author
-
van Erning, F., Vissers, P., Punt, C., Lemmens, V., van Erning, F N, Vissers, P A J, Punt, C J A, and Lemmens, V E P P
- Subjects
COLON cancer treatment ,CANCER chemotherapy ,CANCER prognosis - Abstract
A letter to the editor is presented in response to the article " Effects of Adjuvant Chemotherapy on Recurrence, Survival and Quality of Life in Stage II Colon Cancer Patients: A 24-Month Follow-Up" by C. Lewis and colleagues in a 2016 issue.
- Published
- 2016
- Full Text
- View/download PDF
331. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU)
- Author
-
Cutsem, E. Van, Cunningham, D., Huinink, Ten Bokkel, W., W., Punt, C. J. A., Alexopoulos, C. G., Dirix, L., Symann, M., Blijham, G. H., Cholet, P., and Fillet, G. C.
- Published
- 1999
- Full Text
- View/download PDF
332. Prediction of the systemic exposure to oral 9-amino-20(S)-camptothecin using single-sample analysis.
- Author
-
A, Sparreboom, J, de Jonge M, J, Punt C, J, Loos W, K, Nooter, G, Stoter, G, Porro M, and J, Verweij
- Abstract
The purpose of this study was to develop and validate limited-sampling strategies for prediction of the area under the plasma-concentration time curves (AUCs) of the lactone and total (i. e., lactone plus carboxylate) forms of the novel topoisomerase-I inhibitor 9-amino-20(S)-camptothecin (9-AC). Complete pharmacokinetic curves for both drug species were obtained from 32 patients who received the drug orally in a clinical phase I setting at dose levels ranging from 0.25 to 1.10 mg/m2. The concentrations of the lactone and carboxylate forms of 9-AC in plasma were measured by HPLC. Using data from 20 randomly selected patients, forward-stepwise multivariate regression analysis was used to generate modeling strategies incorporating data from one, two, or three plasma samples. The simultaneous optimal prediction of both 9-AC lactone and 9-AC total AUCs was obtained with sample time points at 0.33, 3.0, and 11.0 h after drug dosing. Validation of the models on an independent data set comprising data of the remaining 12 patients demonstrated that 9-AC lactone and 9-AC total AUCs could be predicted sufficiently unbiased and precise using one and two time points: [AUC (ng. h/ml) = 7.103*C3 + 4.333] for 9-AC lactone and [AUC (ng. h/ml) = 9.612*C3 + 13.77*C11 - 44.11] for 9-AC total, where C3 and C11 represent the 9-AC plasma concentrations in ng/ml at 3 and 11 h after drug dosing. Application of the proposed models will be valuable in the determination of 9-AC population pharmacokinetics and permits treatment optimization for patients on the basis of individual pharmacokinetic characteristics through restricted drug monitoring in clinical routines.
- Published
- 1999
333. Interconnectivity between molecular subtypes and tumor stage in colorectal cancer.
- Author
-
Coebergh van den Braak, R. R. J., ten Hoorn, S., Sieuwerts, A. M., Tuynman, J. B., Smid, M., Wilting, S. M., Martens, J. W. M., Punt, C. J. A., Foekens, J. A., Medema, J. P., IJzermans, J. N. M., and Vermeulen, L.
- Subjects
TUMOR classification ,COLORECTAL cancer ,GENE expression profiling ,MEDICAL records ,BIOLOGY - Abstract
Background: There are profound individual differences in clinical outcomes between colorectal cancers (CRCs) presenting with identical stage of disease. Molecular stratification, in conjunction with the traditional TNM staging, is a promising way to predict patient outcomes. We investigated the interconnectivity between tumor stage and tumor biology reflected by the Consensus Molecular Subtypes (CMSs) in CRC, and explored the possible value of these insights in patients with stage II colon cancer.Methods: We performed a retrospective analysis using clinical records and gene expression profiling in a meta-cohort of 1040 CRC patients. The interconnectivity of tumor biology and disease stage was assessed by investigating the association between CMSs and TNM classification. In order to validate the clinical applicability of our findings we employed a meta-cohort of 197 stage II colon cancers.Results: CMS4 was significantly more prevalent in advanced stages of disease (stage I 9.8% versus stage IV 38.5%, p < 0.001). The observed differential gene expression between cancer stages is at least partly explained by the biological differences as reflected by CMS subtypes. Gene signatures for stage III-IV and CMS4 were highly correlated (r = 0.77, p < 0.001). CMS4 cancers showed an increased progression rate to more advanced stages (CMS4 compared to CMS2: 1.25, 95% CI: 1.08-1.46). Patients with a CMS4 cancer had worse survival in the high-risk stage II tumors compared to the total stage II cohort (5-year DFS 41.7% versus 100.0%, p = 0.008).Conclusions: Considerable interconnectivity between tumor biology and tumor stage in CRC exists. This implies that the TNM stage, in addition to the stage of progression, might also reflect distinct biological disease entities. These insights can potentially be utilized to optimize identification of high-risk stage II colon cancers. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
334. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy
- Author
-
Bent, M. J. van den, Kros, J. M., Heimans, J. J., Pronk, L. C., Groeningen, C. J. van, Krouwer, H. G.J., Taphoorn, M. J.B., Zonnenberg, B. A., Tijssen, C. C., Twijnstra, A., Punt, C. J.A., and Boogerd, W.
- Abstract
To determine the response rate and factors correlated with response of oligodendroglial tumors to procarbazine, lomustine (CCNU), and vincristine (PCV) chemotherapy.
- Published
- 1998
335. False-positive subtraction scintigram of the parathyroid glands due to metastatic tumor
- Author
-
Punt, C. J., de Hooge, P., Hoekstra, J. B., and Other departments
- Subjects
hormones, hormone substitutes, and hormone antagonists - Abstract
A focus of increased uptake on a 201Tl minus 99mTc subtraction scintigram of the parathyroid glands was found in a patient with persistent hypercalcemia. This area was not caused by an abnormal parathyroid gland but by an enlarged lymph node containing metastatic tissue from an adenocarcinoma of the ovary
- Published
- 1985
336. Comparison of symptom clusters associated with fatigue in older and younger survivors of colorectal cancer.
- Author
-
Agasi-Idenburg, S., Thong, M., Punt, C., Stuiver, M., Aaronson, N., Agasi-Idenburg, S C, Thong, M S Y, Punt, C J A, Stuiver, M M, and Aaronson, N K
- Subjects
- *
COLON cancer patients , *SYMPTOMS , *CANCER fatigue , *AGE factors in disease , *DIAGNOSIS of mental depression , *ANXIETY diagnosis , *MENTAL health , *QUALITY of life , *COLON tumors , *FATIGUE (Physiology) , *SYNDROMES , *CROSS-sectional method , *DISEASE complications , *PSYCHOLOGY ,RECTUM tumors - Abstract
Purpose: Cancer-related fatigue (CRF) is one of the most frequently reported symptoms in cancer survivors. To be able to optimally treat CRF, knowledge of symptoms that interact with CRF is helpful. During aging, changes occur in body composition with progressive deterioration in physiological functions and metabolic processes causing a decline of adaptive capacity. Therefore, symptoms caused by cancer and its treatment might coexist in different symptom clusters in older cancer survivors, compared to younger survivors. The purpose of this analysis was to identify and compare symptom clusters that include CRF between older and younger survivors of colorectal cancer (CRC).Methods: Data were drawn from a cross-sectional study from the Netherlands Cancer Registry. In total, 1698 stage I and II CRC survivors diagnosed from 2000 to 2009 completed questionnaires on fatigue and psychological distress. Survivors were categorized in two groups based on age (≤65 versus >65 years) Symptom clusters were assessed using principal component analysis. A sensitivity analysis was performed on the results with categorical principal component analysis.Results: In both age groups, three components including two symptom clusters were identified: an emotional symptom cluster containing anxiety, fatigue, and depression; a pain symptom cluster containing pain and insomnia; and a third component containing dyspnea only.Conclusions: Symptom clusters in survivors of CRC appear to be independent of age. In treating CRC survivors for fatigue, regardless of age, it is advisable to assess depression and anxiety and, if necessary, refer for further diagnosis and treatment. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
337. Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients
- Author
-
Vries, I. J. M., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P. H., Ruiter, D. J., Gerritsen, M. -J P., Croockewit, S., Britten, C. M., Ruurd Torensma, Adema, G. J., Figdor, C. G., and Punt, C. J. A.
- Subjects
Tumor microenvironment [UMCN 1.3] ,Interventional oncology [UMCN 1.5] ,Immunotherapy, gene therapy and transplantation [UMCN 1.4] ,hemic and immune systems ,chemical and pharmacologic phenomena - Abstract
Contains fulltext : 142431.pdf (Publisher’s version ) (Open Access) PURPOSE: We have investigated the capacity of immature and mature monocyte-derived DCs pulsed with melanoma-associated peptides (gp100 and tyrosinase) to induce a primary cytotoxic T-lymphocyte response in vivo. EXPERIMENTAL DESIGN: Advanced HLA-A2.1(+) melanoma patients were vaccinated with peptide- and keyhole limpet hemocyanin (KLH)-pulsed DCs, either immature (9 patients) or matured by monocyte-conditioned medium/tumor necrosis factor alpha/prostaglandin E(2) (10 patients). RESULTS: All patients vaccinated with mature DCs showed a pronounced proliferative T-cell and humoral response against KLH. By contrast, KLH responses were absent in most of the patients vaccinated with immature DCs. Delayed-type hypersensitivity (DTH) reactions against antigen-pulsed DCs were only observed in patients vaccinated with mature DCs and not in patients vaccinated with immature DCs. MHC-peptide tetramer staining of DTH-derived T cells revealed the presence of specific T cells recognizing the melanoma-associated peptides in 1 patient. In a second patient, DTH-derived T cells showed specific lysis of tumor cells expressing the antigens used for DC pulsing. Only patients vaccinated with mature DCs showed objective clinical responses. Interestingly, both patients with long-term progression-free survival (22 and >40 months) were both vaccinated with mature DCs and demonstrated antigen-specific T-cell reactivity of DTH-derived T cells. CONCLUSIONS: We conclude that mature DC are superior to immature DC in the induction of immunological responses in melanoma patients, which may translate into improved clinical results.
338. Dynamic Gadolinium-DTPA-Enhanced MRI and FDG-PET for Chemotherapy Response Evaluation in Colorectal Liver Metastases
- Author
-
Dennis Vriens, Laarhoven, H. W. M., Asten, J. J. A., Krabbe, P. F. M., Visser, E. P., Heerschap, A., Punt, C. J. A., Geus-Oei, L. F., and Oyen, W. J. G.
339. Monitoring the effects of bevacizumab beyond progression in murine colorectal cancer: a functional imaging approach
- Author
-
Heijmen, L., Punt, C. J. A., Ter Voert, E. E. G. W., Geus-Oei, L., Heerschap, A., Bussink, J., Zerbi, V., Wim J.G. Oyen, Span, P. N., Boerman, O., and Laarhoven, H. W. M.
340. A phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors
- Author
-
Giuseppe Giaccone, Punt, C. J. A., Ando, Y., Ruijter, R., Nishi, N., Peters, M., Blomberg, B. M. E., Scheper, R. J., Vliet, H. J. J., Den Eertwegh, A. J. M., Roelvink, M., Beijnen, J., Zwierzina, H., and Pinedo, H. M.
341. South Africa
- Author
-
Kirsten, J., May, J., Hendriks, S., Michael Lyne, Machethe, C. L., and Punt, C.
- Subjects
Development Studies, Economics and Finance, Environment - Abstract
The importance of agricultural growth to poverty reduction is well known, but the specific channels through which the poor can take advantage of growth require further research. Beyond Food Production takes on this challenge, investigating four important channels: rural labor markets, farm incomes, food prices, and linkages to other economic sectors.
342. Vaccine-specific T cell responses in delayed-type hypersensitivity biopsies after dendritic cell vaccination correlate with clinical outcome
- Author
-
Boullart, A. C. I., Vries, I. J. M., Monique Bernsen, Lesterhuis, W. J., Scharenborg, N. M., Figdor, C. G., Adema, G. J., and Punt, C. J. A.
- Abstract
Item does not contain fulltext
343. Individual patient data (IPD) analysis of progression-free survival (PFS) versus overall survival (OS) as an endpoint for metastatic colorectal cancer (mCRC) in modern trials: Findings from the 16,700 patients (pts) ARCAD database
- Author
-
Shi, Q., Gramont, A., Buyse M, E., Grothey, A., Schmoll H, J., Seymour M, T., Adams R, A., Saltz, L., Goldberg R, M., Punt C J, A., Douillard J, Y., Hecht J, R., Hurwitz, H., Diaz Rubio, E., Porschen, R., Tebbutt N, C., Fuchs C, S., Souglakos, J., Alfredo Falcone, Sargent D, J., and FOR THE ARCAD GROUP
344. Successful treatment with chemotherapy and subsequent allogeneic bone marrow transplantation for myeloid blastic crisis of chronic myelogenous leukemia following advanced Hodgkin's disease.
- Author
-
Punt, Cornelis J. A., Rozenberg-Arska, Maja, Verdonck, Leo F., Punt, C J, Rozenberg-Arska, M, and Verdonck, L F
- Published
- 1987
- Full Text
- View/download PDF
345. Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
- Author
-
Punt, CJA, Humblet, Y, Roca, E, Dirix, LY, Wainstein, R, Polli, A, Corradino, I, Punt, C J, and Dirix, L Y
- Published
- 1996
- Full Text
- View/download PDF
346. Skin-derived tumor specific T cells predict clinical outcome in dendritic cell vaccination studies in both stage III and IV melanoma patients.
- Author
-
Aarntzen, E. H. J. G., Lesterhuis, W. J., Van Rossum, M., Adema, G. J., Figdor, C. F., Punt, C. J. A., and De Vries, I. J. M.
- Subjects
MELANOMA - Abstract
The article presents an abstract of research paper on melanoma submitted at the 5th European Workshop on Immune-Mediated Inflammatory Diseases held at Barcelona, Spain, on December 1-3, 2010.
- Published
- 2010
- Full Text
- View/download PDF
347. Randomized Phase III Study of Capecitabine, Oxaliplatin, and Bevacizumab With or Without Cetuximab in Advanced Colorectal Cancer, the CAIRO2 Study of the Dutch Colorectal Cancer Group.
- Author
-
Punt, C. J., Tol, J., and Rodenburg, C. J.
- Abstract
An abstract of the article "Randomized Phase III Study of Capecitabine, Oxaliplatin, and Bevacizumab With or Without Cetuximab in Advanced Colorectal Cancer, the CAIRO2 Study of the Dutch Colorectal Cancer Group," by C.J. Punt, J. Tol and C.J. Rodenburg, is presented.
- Published
- 2008
348. CMR 2005: 9.07: In vivo MR tracking of magnetically labeled dendritic cells: first clinical experience.
- Author
-
Barentsz, J., Verdijk, P., de Vries, I., Lesterhuis, W., Scheenen, T., Boerman, O., Oyen, W., Adema, G., van Krieken, J., Bulte, J., Punt, C., Heerschap, A., and Figdor, C.
- Published
- 2006
- Full Text
- View/download PDF
349. Fotemustine and tamoxifen combination therapy in metastatic malignant melanoma. A phase II study
- Author
-
Punt, C
- Published
- 1995
- Full Text
- View/download PDF
350. Hyperbilirubinaemia in patients treated with recombinant human interleukin-2 (rIL-2)
- Author
-
Punt, CJA, Henzen-Logmans, SC, Bolhuis, RL, Stoter, G, Punt, C J, Henzen-Logmans, S C, and Bolhuis, R L
- Published
- 1990
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.